VHT - Vanguard Health Care ETF

NYSEArca - NYSEArca Delayed Price. Currency in USD

155.87

-1.36 (-0.86%)

At close: 4:00PM EDT

Stock chart is not supported by your current browser

Previous Close	157.23
Open	156.87
Bid	0.00 x 0
Ask	0.00 x 0
Day's Range	155.38 - 157.53
52 Week Range	136.10 - 171.30
Volume	103,792
Avg. Volume	222,541

Net Assets	8.07B
NAV	153.27
PE Ratio (TTM)	64.54
Yield	1.28%
YTD Return	-0.16%
Beta (3y)	0.97
Expense Ratio (net)	0.10%
Inception Date	2004-01-26

Trade prices are not sourced from all markets

InvestorPlace14 days ago
The 3 Best Low-Cost Retirement Funds
When it comes to assessing the cost of a retirement mutual fund or exchange-traded fund, most investors simply look at the absolute value of the expense ratio. The lower the expense ratio, they figure, the better. For some ETFs and funds, the definition of low-cost retirement funds is relative.
Market Realist16 days ago
Analysts’ Recommendations for Johnson & Johnson in March 2018
Analyzing Johnson & Johnson’s Stock and Valuations in March 2018
Market Realist21 days ago
How Merck’s Quarterly Revenues Trended in 2017
What Analysts Recommend for Merck in March 2018
Market Realist23 days ago
Must-Know Developments for Ionis Pharmaceuticals in 2018
How Ionis Pharmaceuticals Is Positioned in 2018
Motley Fool26 days ago
How to Invest in Healthcare Stocks the Easy Way
Here are several smart ways to invest in the companies that keep people healthy.
Market Realistlast month
Assessing Pfizer’s 4Q17 Quarterly Revenue Trend
An Overview of Pfizer's 4Q17: What Lies Ahead?
Market Realistlast month
Changes in Johnson & Johnson’s Profit Margins in 4Q17
Changes in Johnson & Johnson's Valuation in February 2018
Market Realist2 months ago
What’s ahead for Abbott Laboratories’ Medical Device Unit?
What's Next for Abbott Laboratories after a Stellar 2017?
Market Realist3 months ago
Analysts’ Estimates for Eli Lilly’s 4Q17 Earnings
A Preview of Eli Lilly’s 4Q17 Earnings Release on January 31A look at Eli Lilly & Co.
Market Realist3 months ago
What Are Pfizer’s Positive Growth Contributors?
Pfizer’s (PFE) business is classified into two business segments—the Innovative Health segment and Essential Health segment. The products that are expected to contribute towards Pfizer’s revenue growth include Eliquis, Sulperazon, Lipitor, Chantix/Champix, Lyrica IH, Xalkori, Xeljanz, Celebrex, Medrol, and Xtandi. The above chart compares the revenues for Pfizer’s key growth contributors in the past few quarters.
Investopedia3 months ago
Top 3 Healthcare ETFs for 2018
The solid performance of the healthcare market in 2017 has created investment opportunities. These ETFs are poised to take advantage.
Market Realist3 months ago
What Led to Arrowhead Pharmaceuticals’ Revenue Surge in 2017?
Arrowhead Pharmaceuticals: A Promising Drug Pipeline
Market Realist3 months ago
Merck & Co.’s Cardiovascular and Immunology Products in 3Q17
Who’s Watching Merck & Co. in January 2018?
Market Realist3 months ago
Johnson & Johnson’s Pharmaceutical Segment: 4Q17 Estimates
Johnson & Johnson’s 4Q17 Earnings on January 23: What to Expect
Market Realist3 months ago
Insys Has Legal Issues Galore
In December 2016, the U.S. Attorney’s Office for the District of Massachusetts issued an indictment against six former Insys (INSY) employees, which included the company’s former president, CEO, and director Michael Babich. This indictment was on charges including racketeering conspiracy, conspiracy to commit mail fraud, conspiracy to commit wire fraud, and conspiracy to violate the anti-kickback statute.
Market Realist3 months ago
What’s the Competitive Landscape for Accelerate Diagnostics?
How Is Accelerate Diagnostics Positioned at the Start of 2018?
InvestorPlace3 months ago
3 Vanguard ETFs for Retired Investors to Buy Right Now
Vanguard continues to set the bar as far as low-cost mutual funds and ETFs. Low-cost is almost synonymous with its brand. When it comes to retirement, Vanguard ETF choices hold even more sway over investors, as they should.
InvestorPlace3 months ago
3 Trades That Will Make You $1,000 This Month
One of the ways subscribers to my stock and options advisory newsletter, The Liberty Portfolio, generate additional monthly income is by using naked puts. By selling puts, you choose a stock you either own or might want to buy. You sell the right for someone else to put the stock to you, that is, force you to buy it, at a particular price (strike price) on or before a particular date (expiration date).
InvestorPlace3 months ago
7 Best Healthcare ETFs for 2018
Healthcare ETFs saw plenty of fireworks in 2017, thanks in large part to Congress.
Market Realist3 months ago
Examining Incyte’s Quarterly Revenue Trend
New Insights for Incyte Corporation as of January
ETF Trends3 months ago
A Healthy Vanguard Sector ETF
The healthcare sector was one of the best-performing sectors in the S&P 500 last year. Investors looking for more of the same this year can consider an array of exchange traded funds dedicated to the sector, ...
InvestorPlace3 months ago
The Vanguard Health Care ETF Is a Strong Buy After Its Powerful Rally
Vanguard Health Care ETF (NYSEARCA:VHT) was up an impressive 21% this past year, besting the S&P 500 and running close to the Dow Jones Industrial Average for the past 12 months. The point is, healthcare was a tough way to make a 20% gain last year, yet VHT did it and it paid a 1.6% dividend in the process. The VHT ETF is set up to track the MSCI US Investable Market Health Care 25/50 Index.
Market Realist5 months ago
Merck: Diabetes, General Medicine, and Women’s Health after 3Q17
In 3Q17, Merck’s (MRK) Januvia generated revenue of ~$1.0 billion which reflected ~1% growth YoY (year-over-year) and ~7% growth QoQ (quarter-over-quarter). During the first nine months of 2017, Januvia ...
Investopedia5 months ago
Top 3 Healthcare ETFs for 2017
The solid performance of the healthcare market in 2017 has created investment opportunities. These ETFs are poised to take advantage.
Market Realist7 months ago
Quarterly Performance of Eli Lilly’s New Products
Eli Lilly’s (LLY) human pharmaceutical business reported revenues of $5.0 billion in 2Q17, an 11.0% rise compared to $4.5 billion in 2Q16.